Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Nedjad Losic"'
Autor:
Anders Österborg, Roxanne C. Jewell, Swami Padmanabhan-Iyer, Thomas J. Kipps, Jiří Mayer, Stephan Stilgenbauer, Cathy D. Williams, Andrzej Hellmann, Richard R. Furman, Tadeusz Robak, Peter Hillmen, Marek Trnêný, Martin J.S. Dyer, Magdalena Piotrowska, Tomas Kozak, Ira V. Gupta, Jennifer L. Phillips, Nancy Goldstein, Herbert Struemper, Nedjad Losic, Steen Lisby, William G. Wierda
Publikováno v:
Haematologica, Vol 100, Iss 8 (2015)
Externí odkaz:
https://doaj.org/article/19adce254e934f14a1055ceca752c298
Autor:
Eric Van Cutsem, Joelle Collignon, Rikke Eefsen, Sebastian Ochsenreither, Zanete Zvirbule, Audrius Ivanauskas, Camilla Rydberg Millrud, Petter Skoog, Nedjad Losic, Susanne Magnusson, Annika Sanfridson, David Liberg
Publikováno v:
Cancer Research. 83:2172-2172
Background: Interleukin-1 Receptor Accessory Protein (IL1RAP) is expressed on cancer and stromal cells in pancreatic ductal adenocarcinoma (PDAC), and high tumor IL1RAP RNA expression is a negative prognostic marker1. Dimerization between IL1RAP and
Autor:
Astrid Paulus, Saulius Cicenas, Zanete Zvirbule, Luis G. Paz-Ares, Ahmad Awada, Ignacio Garcia-Ribas, Nedjad Losic, Marius Zemaitis
Publikováno v:
Journal of Clinical Oncology. 40:9020-9020
9020 Background: Interleukin-1 Receptor Accessory Protein (IL1RAP) is expressed by cancer and stromal cells of many solid tumors. The IL-1 pathway is active in tumors and upregulated in response to chemotherapy. IL1RAP interacts with IL-1R1 and modul
Autor:
Karsten Nysom, Karen Tornøe, Nedjad Losic, Brian H. Kushner, Daniel A. Morgenstern, Melissa K. Bear, Jaume Mora
Publikováno v:
Journal of Clinical Oncology. 39:10022-10022
10022 Background: NB is the most common extracranial solid tumor in children and half of patients present with high-risk disease. Bone and BM are frequent sites of metastatic disease and can serve as a reservoir for residual disease driving relapse.
Autor:
Torben Plesner, Paul G. Richardson, Tahamtan Ahmadi, Juan Jose Perez Ruixo, Saad Z. Usmani, Sagar Lonial, Pamela L. Clemens, Richard Jansson, Henk M. Lokhorst, Honghui Zhou, Peter M. Voorhees, Xu Steven Xu, Kevin Liu, Xiaoyu Yan, Thomas A. Puchalski, Nedjad Losic, Robert Z. Orlowski, Kristen Lantz
Publikováno v:
Clinical Pharmacokinetics
Clinical Pharmacokinetics, 57(4), 529-538. Adis International Ltd
Yan, X, Clemens, P L, Puchalski, T, Lonial, S, Lokhorst, H, Voorhees, P M, Usmani, S, Richardson, P G, Plesner, T, Liu, K, Orlowski, R Z, Losic, N, Jansson, R, Ahmadi, T, Lantz, K, Ruixo, J J P, Zhou, H & Xu, X S 2018, ' Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma ', Clinical Pharmacokinetics, vol. 57, no. 4, pp. 529-538 . https://doi.org/10.1007/s40262-017-0598-1
Clinical Pharmacokinetics, 57(4), 529-538. Adis International Ltd
Yan, X, Clemens, P L, Puchalski, T, Lonial, S, Lokhorst, H, Voorhees, P M, Usmani, S, Richardson, P G, Plesner, T, Liu, K, Orlowski, R Z, Losic, N, Jansson, R, Ahmadi, T, Lantz, K, Ruixo, J J P, Zhou, H & Xu, X S 2018, ' Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma ', Clinical Pharmacokinetics, vol. 57, no. 4, pp. 529-538 . https://doi.org/10.1007/s40262-017-0598-1
Objective The aim of this study was to understand the influence of disease and patient characteristics on exposure to daratumumab, an immunoglobulin Gκ (IgGκ) monoclonal antibody, and clinical outcomes in relapsed or refractory multiple myeloma (MM
Autor:
Bart de Jong, Pernille Autzen Usher, Patrick J. Engelberts, Danita H. Schuurhuis, Arnout F. Gerritsen, Roberto S. Oliveri, Theodora W. Salcedo, Esther C.W. Breij, Marten van der Zee, Ida H. Hiemstra, Jeroen J. Lammerts van Bueren, Paul W. H. I. Parren, Janine Schuurman, Sjeng Horbach, Sandra Verploegen, Nedjad Losic
Publikováno v:
Blood. 132:1664-1664
DuoBody®-CD3xCD20 (GEN3013) is a bispecific antibody (bsAb), recognizing the T-cell antigen CD3 and the B-cell antigen CD20, that triggers potent T-cell-mediated lysis of CD20-expressing cells. DuoBody-CD3xCD20 is a full-length bispecific IgG1 gener
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
Autor:
Tomas Kozak, Geoffrey W. Chan, Randy Davis, Peter Hillmen, Cathy D. Williams, Charlotte A. Russell, Richard R. Furman, Marek Trneny, Nedjad Losic, Anders Österborg, Tadeusz Robak, Magdalena Piotrowska, Thomas J. Kipps, Stephan Stilgenbauer, Joris Wilms, William G. Wierda, Jiří Mayer, Swami Padmanabhan, Andrzej Hellmann, Martin J. S. Dyer
Publikováno v:
Journal of Clinical Oncology. 28:1749-1755
Purpose New treatments are needed for patients with fludarabine- and alemtuzumab-refractory (FA-ref) chronic lymphocytic leukemia (CLL) or patients with fludarabine-refractory CLL with bulky (> 5 cm) lymphadenopathy (BF-ref) who are less suitable for
Autor:
Brian K. Link, Pieter Sonneveld, Michael Kneba, Marek Z. Wojtukiewicz, Ole V. Gadeberg, Peter Johnson, John Radford, Jørgen Petersen, Michael Pfreundschuh, Nedjad Losic, Andreas Engert, Anton Hagenbeek, Lars Møller Pedersen, Tadeusz Robak, Jan Walewski, Mimi Flensburg, Andrzej Hellmann
Publikováno v:
Hagenbeek, A, Gadeberg, O V, Johnson, P, Pedersen, L M, Walewski, J, Hellmann, A, Link, B K, Robak, T, Wojtukiewicz, M, Pfreundschuh, M, Kneba, M, Engert, A, Sonneveld, P, Flensburg, M, Petersen, J, Losic, N & Radford, J 2008, ' First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma : results of a phase 1/2 trial ', Blood, vol. 111, no. 12, pp. 5486-5495 . https://doi.org/10.1182/blood-2007-10-117671
Blood, 111(12), 5486-5495. American Society of Hematology
Blood, 111(12), 5486-5495. American Society of Hematology
Ofatumumab is a unique monoclonal antibody that targets a distinct small loop epitope on the CD20 molecule. Preclinical data show that ofatumumab is active against B-cell lymphoma/chronic lymphocytic leukemia cells with low CD20-antigen density and h
Autor:
Thomas J. Kipps, Tomas Kozak, Magdalena Piotrowska, William G. Wierda, Nancy Goldstein, Jiří Mayer, Marek Trnêný, Roxanne C. Jewell, Nedjad Losic, Herbert Struemper, Swami Padmanabhan-Iyer, Stephan Stilgenbauer, Martin J. S. Dyer, Richard R. Furman, Tadeusz Robak, Andrzej Hellmann, Ira Gupta, Peter Hillmen, Cathy D. Williams, Steen Lisby, Jennifer Phillips, Anders Österborg
Publikováno v:
Haematologica.
While fludarabine-based regimens are a standard for treatment of chronic lymphocytic leukemia (CLL), patients who become refractory to fludarabine have had low response rates with salvage therapy and poor survival outcomes.1–3 We reported that ofat
Autor:
Jacob P. Laubach, Clarissa M. Uhlar, A. Kate Sasser, Jianping Wang, Nedjad Losic, Markus Hansson, Monique C. Minnema, Antonio Palumbo, Paul G. Richardson, Henk M. Lokhorst, Linda Basse, Peter Gimsing, Jakub Krejcik, Tahamtan Ahmadi, Hareth Nahi, Ulrik Lassen, Nikolai Constantin Brun, Niels W.C.J. van de Donk, Torben Plesner, Imran Khan, Steen Lisby
Publikováno v:
Lokhorst, H M, Plesner, T, Laubach, J P, Nahi, H, Gimsing, P, Hansson, M, Minnema, M C, Lassen, U, Krejcik, J, Palumbo, A, van de Donk, N W C J, Ahmadi, T, Khan, I, Uhlar, C M, Wang, J, Sasser, A K, Losic, N, Lisby, S, Basse, L, Brun, N & Richardson, P G 2015, ' Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma ', New England Journal of Medicine, vol. 373, no. 13, pp. 1207-1219 . https://doi.org/10.1056/NEJMoa1506348
New England Journal of Medicine, 373(13), 1207. Massachussetts Medical Society
New England Journal of Medicine, 373(13), 1207-1219. Massachussetts Medical Society
Lokhorst, H M, Plesner, T, Laubach, J P, Nahi, H, Gimsing, P, Hansson, M, Minnema, M C, Lassen, U, Krejcik, J, Palumbo, A, van de Donk, N, Ahmadi, T, Khan, I, Uhlar, C M, Wang, J, Sasser, A K, Losic, N, Lisby, S, Basse, L, Brun, N & Richardson, P G 2015, ' Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma ', The New England Journal of Medicine, vol. 373, no. 13, pp. 1207-1219 . https://doi.org/10.1056/NEJMoa1506348
New England Journal of Medicine, 373(13), 1207. Massachussetts Medical Society
New England Journal of Medicine, 373(13), 1207-1219. Massachussetts Medical Society
Lokhorst, H M, Plesner, T, Laubach, J P, Nahi, H, Gimsing, P, Hansson, M, Minnema, M C, Lassen, U, Krejcik, J, Palumbo, A, van de Donk, N, Ahmadi, T, Khan, I, Uhlar, C M, Wang, J, Sasser, A K, Losic, N, Lisby, S, Basse, L, Brun, N & Richardson, P G 2015, ' Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma ', The New England Journal of Medicine, vol. 373, no. 13, pp. 1207-1219 . https://doi.org/10.1056/NEJMoa1506348
BACKGROUND Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1–2 trial involving patients with relapsed myeloma or relapsed myeloma that was refractory to two o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b091a32c87a186a362edd84a61a4d327
https://research.vumc.nl/en/publications/2be494d7-0687-42a3-8411-f552b1cd5a84
https://research.vumc.nl/en/publications/2be494d7-0687-42a3-8411-f552b1cd5a84